Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Visiongain Reports | Women's Reproductive Disorders Therapeutics 2008-2018

Women's Reproductive Disorders Therapeutics 2008-2018

Visiongain predicts that there is great potential for the women’s reproductive disorders therapeutics market from present onwards, as this new report Women’s Reproductive Disorders Therapeutics, 2008-2018 shows.

Oral Contraceptive Market

The systemic hormonal contraceptive market is currently a $7bn market, with hormonal oral contraceptives dominating the market for many years. The oral pills are increasingly facing competition from other routes of delivery. With patent expiration, several companies have begun manufacturing generic products. Hormonal contraceptives for women have become the benchmark for the safety and effectiveness of birth control methods.

Although hormonal contraceptives are already a very mature market, visiongain believes that there is still room for further growth. In addition, modern basic research has identified some completely new approaches for the contraceptives of the future. Hormonal oral contraceptives will continue to play an important role in birth control from 2008 to 2018.

Lifecycle Management and Product Line Extension

The hormonal oral contraceptive market is undergoing both lifecycle management and product line extension of existing products in the market. There are progestin-only preparations and combined preparations containing an oestrogen and a progestin. Bayer Schering is developing a pill containing various forms of progestin. Clinical studies show that the new drospirenone pill has an apparent therapeutic effect on premenstrual dysphoria - a particularly severe form of the premenstrual syndrome (PMS), as well as on acne. Pills are increasingly being developed with reduced oestrogen dosages. Visiongain evaluates the prospects for extended or continuous administration of oral contraceptives. It is becoming popular for the treatment of endometriosis, dysmenorrhoea and menstrual-associated symptoms.

Menopause and Hormone Replacement Therapy

HRT has been the subject of considerable discussion recently. In light of recent and current studies, visiongain provides comprehensive market information on HRT market prospects from 2008 to 2018.

Women’s Reproductive Disorders Therapeutics, 2008-2018 examines that market critically, through comprehensive primary and secondary research. In addition to consultation with industry opinion, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based study with detailed financial analyses and informed opinion on the future of the women’s reproductive health market.

In particular, our new Women’s Reproductive Disorders Therapeutics, 2008-2018 report concentrates on the following essential aspects of that market:

• Overview of the women’s reproductive therapies market

• Key industrial players in the global women’s reproductive therapies market

• Forecasts of global market from 2008-2018, including forecasts of the leading therapeutic agents in this market area

• Forecasts for therapies in the seven leading pharmaceutical markets

• Drivers and opportunities in the global women’s reproductive therapies market

• Restraints and threats in the global women’s reproductive therapies market

• Primary research, with full interview transcripts

• Coverage of pipeline developments, with discussion of trends from the present onwards

Why You Should Buy This Report

In Women’s Reproductive Disorders Therapeutics, 2008-2018 you will receive the following essential information for understanding the women’s reproductive disorders therapeutics market and industry:

• The value of the women’s reproductive disorders therapeutics market and its principal market segments from 2008 to 2018

• Which current or future therapies that will drive the market for women’s reproductive disorders therapeutics from 2008 to 2018, with detailed sales forecasts

• Market drivers and restraints, including a comprehensive SWOT analysis for women’s reproductive disorders therapeutics

• The companies involved in the market and their business strategies

This Report would be Useful to the Following Professionals, Amongst Others:

• Business managers of pharmaceutical industry related to women’s reproductive disorders therapeutics

• Researchers, analysts and academics interested in women’s reproductive disorders therapeutics

• Senior staff in healthcare authorities relevant to women’s reproductive disorders therapeutics

• Investors in the pharmaceutical industry relevant to women’s reproductive disorders therapeutics

• Other interested business managers of multinational companies relevant to women’s reproductive disorders therapeutics

• Other business managers of domestic companies

• Academics, researchers and media

* Publication date: 30/09/2008

* Number of Pages: 100

Table of Contents

License

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions